Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Breast Cancer Gene Expression Signatures: Development And Clinical Significance-a Narrative Review

Breast cancer gene expression signatures: development and clinical significance-a narrative review

Siyan Li1, Xinmiao Yu1, Yingying Xu1

  • 1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.

Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
|May 16, 2024

Related Experiment Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.0K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K

View abstract on PubMed

Summary
This summary is machine-generated.

Breast cancer gene expression signatures aid in treatment decisions for early-stage disease. While commercial tests offer prognostic insights, comprehensive clinical assessment remains crucial for personalized patient care.

Area of Science:

  • Oncology
  • Genomics
  • Translational Medicine

Background:

  • Gene expression signatures are rapidly advancing for breast cancer.
  • They aim to elucidate tumor biology and refine clinical treatment strategies.

Purpose of the Study:

  • To review controversies and consensus on gene expression signatures in clinical practice.
  • To offer perspectives and recommendations for future research directions.

Main Methods:

  • A review of English-language PubMed publications.
  • Focus on breast cancer gene expression signatures from 2002 to 2022.

Main Results:

  • Five commercial signatures (Oncotype, MammaPrint, Prosigna/PAM50, EndoPredict, BCI) provide prognostic and predictive assessments.
Keywords:
Breast cancergene expression signaturepredictionprognosis

Related Experiment Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.0K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K
  • Their clinical application is challenging; treatment decisions require integrated clinical-pathological factors.

    • Conclusions:

    • Gene expression signatures can guide adjuvant therapy for early-stage breast cancer, potentially sparing low-risk patients chemotherapy.
    • Further data are needed for radiotherapy, extended endocrine therapy, and neoadjuvant treatments.
    • Personalized treatment requires comprehensive assessment beyond a single factor.